

# CovPall: Improving palliative care for people affected by the COVID-19 pandemic by sharing learning – the national and international response

<b>Submission date</b> 05/05/2020	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 27/07/2020	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 06/08/2024	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

The COVID-19 pandemic is placing an unprecedented strain on health services, with an estimated 1-4% of people dying from this new disease. Some of the symptoms, such as breathlessness, fever, agitation and pain, are very distressing. But in this new disease these symptoms are not well understood. Palliative care services are adapting rapidly to this situation, but in different ways, not knowing what is best.

This research aims to rapidly evaluate the palliative care response in COVID-19 to improve care in the future. There are two main components, called work packages, to the research.

### Added 11/05/2021:

In December 2020 the researchers received additional funding following a rapid call for COVID-19 data research initiatives by Health Data Research UK, Office for National Statistics and UK Research and Innovation (UKRI) to 'build on existing UKRI and NIHR work to use national data to answer key COVID-19 research questions' (<https://www.hdruk.ac.uk/news/projects-to-accelerate-use-of-data-for-vital-covid-19-research/>). This project is an extension of CovPall and is called CovPall-Connect.

### Who can participate?

WP1. Voluntary hospices, hospital based palliative care teams, home care/community teams and other services that offer palliative and/or end of life care.

WP2. Services participating in WP1 from the UK, able to collect information on  $\geq 10$  patients in their care. We aim to recruit ~20 services across settings (hospital, community, voluntary hospice), and areas with different cultural/ethnic and socioeconomic diversities.

### What does the study involve?

There are two main components, called work packages, to the research.

WP1 will survey, UK wide, palliative care clinical leads in different services, about their changes in practice, how they use the workforce and volunteers and what symptom management they

are using. Later, we will collect some more detailed information from a small number of services through interviewing them.

WP2 collects data about patients' symptoms, how they change over time, and the effects of treatments.

Added 11/05/2021:

CovPall-Connect will use national data to boost findings from CovPall. The researchers hope to allow the use of CovPall data for other research. They will assess how the response to COVID-19 affects a number of factors, looking at the following:

- Whether the number of people dying during COVID-19 was reported correctly, or if some deaths were missed
- The number of cases of COVID-19 in the UK population
- The number of people admitted to hospital with COVID-19 and the number of people discharged
- Business, financial and social impacts of COVID-19
- How charities have supported health services and how this information can be captured
- How palliative care information should be collected in the future, focusing on patients with more than one illness

What are the possible benefits and risks of participating?

The research team will draw on their considerable experience in conducting research in this area to ensure a design sensitive to this professional and patient group. We have worked with service teams to discuss the acceptability of the research aims, design and local implementation.

WP1: Qualitative case studies: Interviews will be organised at a time and place to suit the participants, and conducted by researchers with experience of discussing sensitive topics.

Written consent will be obtained from all participants in the qualitative case studies, and regular checks made that participants are happy to continue. Arrangements will be made to inform participants of support agencies if required. The main anticipated risk is that of becoming unduly distressed whilst discussing issues associated with the extreme challenges of the COVID-19 pandemic. We will work to minimise this risk by conducting the interviews in a sensitive and responsive manner, drawing on our research and clinical experience in this field. We have a clear distress protocol to be followed during the research should any distress be apparent or detected during data collection.

There is also the possibility that participants may disclose information about care which reveals risk or poor practice. If they do, this situation will be discussed with the participant and their views on sharing this information with a senior member of staff sought. Where possible their views will be respected, but if a situation is revealed which severely compromises their own or others health or wellbeing, the researcher will inform the participant that they have a duty to disclose this information to the most relevant person.

WP2: We have designed this data collection to be feasible in the current circumstances by minimising the burden on the direct clinical care team whilst maintaining patient confidentiality. There is no burden

We are collecting individual-level pseudonymised patient data that will be securely transferred to the research team at Kings College London via REDcap. This is done by sending via secure email (e.g. NHS mail) each participating service a unique set of 11 randomly generated codes. They use one code per patient about which they enter information. They keep a local record of the details of which patient has been assigned to which code, but this information is not transferred to the research team. The REDcap database does not include any identifying features, including the name of the service, its region, nor any patient identifiable details. ). Obtaining patient consent in the current situation is not feasible therefore we have minimised the dataset to remove any confidential patient information e.g. changed date of birth to age, postcode to LSOA.

These will still be individual-level data, albeit pseudonymised, so we will ensure that these data are transferred securely between research sites and Kings College London. Once on the Kings College London server they will be held securely on password-protected encrypted files. Current infection control policies restrict our ability to display posters at the study sites, but transparency statements will be made available on the Kings College website and all participating study sites so that patients are informed of this study.

Where is the study run from?

1. Cicely Saunders Institute, King's College London (UK) in collaboration with:
2. Wolfson Palliative Care Research Centre at the University of Hull (UK)
3. Martin House Research Centre at the University of York (UK)
4. International Observatory on End of Life Care at Lancaster University (UK)

When is the study starting and how long is it expected to run for?

April 2020 to November 2021

Who is funding the study?

1. Jointly funded by UK Research and Innovation (Medical Research Council) and NIHR (COV0011; MR/V012908/1) (UK)
2. Cicely Saunders International (UK)
3. HDRUK (UK) (HDRUK2020.145)

Who is the main contact?

Mev Hocaoglu or Rachel Cripps (palliativecare@kcl.ac.uk)

### **Study website**

<https://www.kcl.ac.uk/research/covpall>

## **Contact information**

### **Type(s)**

Public

### **Contact name**

Miss Rachel Cripps

### **Contact details**

King's College London  
Bessemer Road  
London  
United Kingdom  
SE5 9PJ

-

palliativecare@kcl.ac.uk

### **Type(s)**

Scientific

### **Contact name**

Prof Irene Higginson

**Contact details**

King's College London  
Bessemer Road  
London  
United Kingdom  
SE5 9PJ  
+44 (0)207 848 5516  
irene.higginson@kcl.ac.uk

**Additional identifiers****EudraCT/CTIS number**

Nil known

**IRAS number**

282824

**ClinicalTrials.gov number**

Nil known

**Secondary identifying numbers**

LRS-19/20-18541, IRAS 282824

**Study information****Scientific Title**

Rapid evaluation of the COVID-19 pandemic response in PALLiative and end of life care: national delivery, workforce and symptom management (CovPall)

CovPall-Connect: Evaluation of the COVID-19 pandemic response in palliative and end of life care: connecting to boost impact and data assets

**Acronym**

CovPall; CovPall-Connect

**Study objectives**

The aim of this study is to evaluate the UK palliative care and end-of-life care response to COVID-19 in terms of services, workforce and symptom management to provide rapid clinical and policy guidance to optimise the response of palliative care clinicians and services to the COVID-19 pandemic.

Added 11/05/2021:

CovPall-Connect: The aim of the study is to understand the relationship between regional COVID-19 palliative care responses and COVID-19 prevalence, mortality, admissions, discharges, business/social impacts through data linkage with national datasets.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

1. Approved 21/04/2020, King's College London Research Ethics committee (Franklin Wilkins Building, 5.9 Waterloo Bridge Wing, Waterloo Road, London, SE1 9NH, UK; +44 (0)20 7848 4020; rec@kcl.ac.uk), ref: LRS-19/20-18541
2. Approved 15/05/2020, Health Research Authority (HRA) and NHS Research Ethics Committee (Barlow House, 3rd Floor, 4 Minshull Street, Manchester, M1 3DZ, UK; +44 (0)207 104 8010; approvals@hra.nhs.uk), ref: 20/NW/0258

## **Study design**

Observational online survey and qualitative case studies followed by cohort study

Added 11/05/2021: CovPall-Connect: Data linkage

## **Primary study design**

Observational

## **Secondary study design**

Longitudinal study

## **Study setting(s)**

Other

## **Study type(s)**

Other

## **Participant information sheet**

<https://www.kcl.ac.uk/cicelysaunders/research/images/covpall-survey-wp1-information-sheet-v3.pdf>

## **Health condition(s) or problem(s) studied**

COVID-19 (SARS-CoV-2 infection), palliative and end of life care

## **Interventions**

WP1: Online survey of palliative care providers, with in-depth qualitative case study of sampled providers. Data will be collected using REDCap.

WP2: Cohort study of people with COVID-19 receiving palliative care input, with data collected at four timepoints, at first assessment (baseline, T0), 24-hour follow-up, ideally twice, but this will depend on survival (T1, T2), and then at death or discharge (D or Di).

WP1 and WP2 are run quickly, (phase I) and analysed. Then both WP1 and WP2 are repeated 6-8 weeks later (phase II), when case studies are added, to gauge key changes.

## **Intervention Type**

Other

## **Primary outcome measure**

WP1. Innovations in services, workforce and volunteer deployment, and their impacts on care and bereavement services; identification of good practice, and sharing of approaches and knowledge. Change in practice, most effective treatments collected at baseline and 6-8 weeks later

WP2. Symptom and problem assessment measured using IPOS score at first assessment

(baseline, T0), 24-hour follow-up, ideally twice, but this will depend on survival (T1, T2), and then at death or discharge (D or Di)

### **Secondary outcome measures**

There are no secondary outcome measures

### **Overall study start date**

01/04/2020

### **Completion date**

30/11/2021

## **Eligibility**

### **Key inclusion criteria**

WP1: Clinical leads of palliative and hospice care services including: palliative care teams in acute hospitals, in-patient hospices/palliative care wards and palliative care community services providing care in peoples own homes and supporting care homes, usually for adults and children. WP2: Consecutive patients supported by the participating palliative care services in WP1 (including remote consultation), with clinically diagnosed and/or test confirmed COVID-19 diagnosis. This will include patients with and without pre-existing progressive conditions.

### **Participant type(s)**

Mixed

### **Age group**

Mixed

### **Sex**

Both

### **Target number of participants**

WP1: Targeted invitation to participate directed to providers of specialist palliative and end-of-life care services in the UK; estimated responses from 390 services. WP2: 200 patients receiving palliative care. 9-11 consecutive patients per service from 20 services, would give baseline data on 180-220 patients, follow-up data on 80-100 (allowing for 50-60% attrition from those who die too quickly to give more than baseline or baseline plus T1, estimate based on audit in one service). 80 patients with follow-up data are needed to detect a difference of 5 points on IPOS (SD=6) between two groups (80 percent power, two-sided 0.05 significance level, mean MCID, SD based on previous research). This sample size will also allow the researchers to identify clear subgroups and actual mean and SDs to enable them to develop hypotheses and sample size calculation for the future.

### **Total final enrolment**

1030

### **Key exclusion criteria**

WP1: No lead or delegate available

WP2: Patients who are <18 years old

**Date of first enrolment**

24/04/2020

**Date of final enrolment**

21/02/2021

## **Locations**

**Countries of recruitment**

Argentina

Australia

Brazil

Canada

England

India

Ireland

Netherlands

Portugal

South Africa

Switzerland

United Kingdom

**Study participating centre**

**Cicely Saunders Institute at King's College London**

Bessemer Road

London

United Kingdom

SE5 9PJ

**Study participating centre**

**Wolfson Palliative Care Research Centre at University of Hull**

Allam Medical Building, University of Hull

Hull

United Kingdom

HU6 7RX

**Study participating centre****Martin House Research Centre at University of York**

Area 2 Seebohm Rowntree Building

Heslington

United Kingdom

YO10 5DD

**Study participating centre****International Observatory on End of Life Care at Lancaster University**

Furness College, Hazelrigg Lane

Lancaster

United Kingdom

LA1 4YG

## **Sponsor information**

**Organisation**

King's College London

**Sponsor details**

Franklin Wilkins Building

5.9 Waterloo Bridge Wing

Waterloo Road

London

England

United Kingdom

SE1 9NH

+44 (0)20 7848 4020

rec@kcl.ac.uk

**Sponsor type**

University/education

**Website**

<http://www.kcl.ac.uk/index.aspx>

**ROR**

<https://ror.org/0220mzb33>

**Organisation**

King's College Hospital NHS Foundation Trust



**Sponsor details**

Research and Innovation Office  
161 Denmark Hill  
London  
England  
United Kingdom  
SE5 8EF  
+44 (0)20 3299 1980  
kch-tr.research@nhs.net

**Sponsor type**

Hospital/treatment centre

**Website**

<https://www.kch.nhs.uk/>

**ROR**

<https://ror.org/01n0k5m85>

**Funder(s)****Funder type**

Government

**Funder Name**

NIHR ARC South London

**Funder Name**

Cicely Saunders International

**Funder Name**

UK Research and Innovation

**Alternative Name(s)**

UKRI

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United Kingdom

## **Funder Name**

Health Data Research UK (HDRUK)

# **Results and Publications**

## **Publication and dissemination plan**

The researchers will release the first results (from phase 1) after WP1 is completed at around 2-3 months into the project, for WP2, at 3 months. They will conduct a midpoint analysis during the study to determine whether there are emerging findings, which they should report. These will be reported to the study steering committee. Phase II will give more reflective and larger analysis where it will be possible to collect additional data and conduct case studies. This will help also if the pandemic/epidemic risks returning.

The final analysis and report (12 months) will also provide a blueprint for the management in future COVID-19 or similar epidemics/pandemics.

Added 11/05/2021:

CovPall-Connect: dissemination of findings via blogs, presentations (April-May 2021). Virtual workshop to engage stakeholders & PPIE regarding findings and recommendations to capture main issues using graphic recording (visualising the content discussion by drawing it live) and voting on main recommendations.

2021 research report in <https://www.mariecurie.org.uk/globalassets/media/documents/policy/policy-publications/2021/better-end-of-life-research-report.pdf> (added 11/05/2021)

## **Intention to publish date**

24/04/2021

## **Individual participant data (IPD) sharing plan**

The datasets generated during and/or analysed during the current study are/will be available upon request from Prof. Irene Higginson ([palliativecare@kcl.ac.uk](mailto:palliativecare@kcl.ac.uk)).

Type of data: CovPall: WS1. A cross-sectional online survey of palliative care services & hospices.

When data will become available and for how long: The researchers welcome data access requests for WP1. Applications for use of the survey data can be made for up to 10 years.

What access criteria data will be shared including with whom, for what types of analyses, and by what mechanism: Data access requests will be considered on a case by case basis on receipt of a methodological sound proposal to achieve aims in line with the original protocol. The study protocol is available on request. All requests for data access should be addressed to the Chief Investigator (Prof. Irene J Higginson; [palliativecare@kcl.ac.uk](mailto:palliativecare@kcl.ac.uk)) and will be reviewed by the Study Steering Group.

Whether consent from participants was obtained: Completion of the survey implied consent.

Comments on data anonymisation: An important component is the sharing of data among the collaborators for the benefit of patients and families, for education, research and improving

care. Ethical and other agreements with participants included an explicit clause to share anonymised data that was collected as part of CovPall.  
Any ethical or legal restrictions: Data access requests will be considered on a case by case basis.

## IPD sharing plan summary

Available on request

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Preprint results</a>	non-peer-reviewed survey results on service innovation and practice change in preprint	03/11/2020	19/03/2021	No	No
<a href="#">Results article</a>	survey results on challenges	05/02/2021	19/03/2021	Yes	No
<a href="#">Funder report results</a>		01/04/2021	24/11/2021	No	No
<a href="#">Study website</a>	CovPall		24/11/2021	No	No
<a href="#">Study website</a>	CovPall-connect		24/11/2021	No	No
<a href="#">Protocol file</a>	version 4.0	28/10/2020	19/10/2022	No	No
<a href="#">HRA research summary</a>			28/06/2023	No	No
<a href="#">Results article</a>		08/02/2022	06/08/2024	Yes	No
<a href="#">Results article</a>		23/03/2021	06/08/2024	Yes	No
<a href="#">Results article</a>	Charitably funded hospices and the challenges associated with the COVID-19 pandemic: a mixed-methods study (CovPall)	10/10/2022	06/08/2024	Yes	No
<a href="#">Results article</a>	Prohibit, Protect, or Adapt? The Changing Role of Volunteers in Palliative and Hospice Care Services During the COVID-19 Pandemic. A Multinational Survey (Covpall)	01/10/2022	06/08/2024	Yes	No
<a href="#">Results article</a>	Symptom management in people dying with COVID-19: multinational observational study	08/09/2022	06/08/2024	Yes	No